Molecular cancer therapeutics
Preclinical development and a case report of a nanobody-based CLDN18.2 CAR-T IMC002 with reduced on-target off-tumor toxicity.
Sicheng Du, Ying Zhang, Ruidong Hao, Lupeng Qiu, Chao Li, Yuting Li, Rong-Rui Liu, Chuan-Hua Zhao, Juan Li, Sisi Ye, Jun Zhou, Yantao Li, Qiaoyong Yi, Shuangshuang Zhang, Minmin Sun
Published: 202510.1158/1535-7163.MCT-25-0171
Abstract
Claudin18.2 (CLDN18.2)-targeted chimeric antigen receptor T (CAR-T) cell therapy has shown promising antitumor activity in gastrointestinal cancers. However, limited persistence in solid tumors and on-target off-tumor (OTOT) toxicity remain significa…
Preview only. Read the full abstract at the source